Lactate Kinetics as a Predictor of Survival in ACLF With Septic Shock

Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how levels of lactate in the body can help predict survival in patients with acute on chronic liver failure who are experiencing septic shock. Septic shock is a serious condition that happens when the body has a severe reaction to an infection, leading to low blood pressure and reduced blood flow to organs. The researchers want to understand if measuring lactate levels can provide important information about a patient's health and chances of recovery.

To participate in this trial, individuals must be aged 18 to 70 and diagnosed with acute on chronic liver failure along with septic shock, as defined by specific medical guidelines. However, some people will not be eligible, including those with certain heart issues, kidney failure, severe lung disease, or other serious conditions. Participants will be asked to provide informed consent and will be monitored closely throughout the study. This research aims to improve understanding and treatment of septic shock in patients with liver problems, and the findings could help doctors make better decisions in critical situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients of Acute on chronic liver failure with septic shock (APASL, Sepsis -3 definitions)
• • 2. Age 18-70yrs
• • 3. Informed Consent
• Exclusion Criteria:
• • 1. Acute coronary syndrome, hemodynamically unstable arrhythmias
• • 2. CKD stage 5
• • 3. COPD with acute exacerbation
• • 4. Acute CVA or Seizures
• • 5. Extremely moribund patients
• • 6. Hepato-cellular carcinoma (HCC), intrahepatic or extrahepatic malignancy
• • 7. Pregnancy
• • 8. Diabetic ketoacidosis